🇺🇸 FDA
Pipeline program

CD19-Targeted NEX-T CAR T, FLUDARABINE PHOSPHATE, CYCLOPHOSPHAMIDE, TOCILIZUMAB, CYCLOPHOSPHAMIDE, FLUDARABINE, CYCLOPHOSPHAMIDE

CA061-1011

Phase 2 small_molecule active

Quick answer

CD19-Targeted NEX-T CAR T, FLUDARABINE PHOSPHATE, CYCLOPHOSPHAMIDE, TOCILIZUMAB, CYCLOPHOSPHAMIDE, FLUDARABINE, CYCLOPHOSPHAMIDE for Lupus Nephritis, Systemic Lupus Erythematosus is a Phase 2 program (small_molecule) at Celgene Europe Limited with 1 ClinicalTrials.gov record(s).

Program details

Company
Celgene Europe Limited
Indication
Lupus Nephritis, Systemic Lupus Erythematosus
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials